Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 3, 2011, Pages

  Lauzier, Benjamin ^a   Vaillant, Fanny ^a   Gélinas, Roselle ^a   Bouchard, Bertrand ^a   Brownsey, Roger ^c   Thorin, Eric ^a   Tardif, Jean Claude ^b   des Rosiers, Christine ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Isolated working heart; Ivabradine; blockers; Substrate metabolism

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; IVABRADINE; LACTATE DEHYDROGENASE; METOPROLOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENERGY METABOLISM; ENERGY YIELD; ENZYME SUBSTRATE; EX VIVO STUDY; GLYCOLYSIS; HEART ATRIUM PACING; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE; HEART RATE REDUCTION; HEART STROKE VOLUME; HEART WORK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE LEVEL;

EID: 79955057003     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01034.2010     Document Type: Article

References (49)

1. Abbott JA, Broadstone RV, Ward DL, Pyle RL. Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. Am J Vet Res 66: 637-641, 2005.
2. Allard MF, Parsons HL, Saeedi R, Wambolt RB, Brownsey R. AMPK and metabolic adaptation by the heart to pressure overload. Am J Physiol Heart Circ Physiol 292: H140-H148, 2007.
3. An D, Kewalramani G, Qi D, Pulinilkunnil T, Ghosh S, Abrahani A, Wambolt R, Allard M, Innis SM, Rodrigues B. β-Agonist stimulation produces changes in cardiac AMPK and coronary lumen LPL only during increased workload. Am J Physiol Endocrinol Metab 288: E1120-E1127, 2005.
4. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292: 2227-2236, 2004.
5. Bangalore S, Kamalakkannan G, Messerli FH. Beta-blockers: no longer an option for uncomplicated hypertension. Curr Cardiol Rep 9: 441-446, 2007.
6. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376: 886-894, 2010.
7. Borer JS, Tardif JC. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol 105: 29-35, 2010.
8. Ceconi C, Cargnoni A, Francolini G, Parinello G, Ferrari R. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc Res 84: 72-82, 2009.
9. Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF, Berdeaux A. Differential effects of heart rate reduction and β-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 282: H672-H679, 2002.
10. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 308: 236-240, 2004.
11. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, Berdeaux A. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 284: H676-H682, 2003.
12. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 120: 10-27, 2007.
13. Di Verniero C, Hocht C, Opezzo JA, Taira CA. Changes in the in vitro pharmacodynamic properties of metoprolol in atria isolated from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 34: 161-165, 2007.
14. Di Verniero CA, Silberman EA, Mayer MA, Opezzo JA, Taira CA, Hocht C. In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. J Cardiovasc Pharmacol 51: 532-541, 2008.
15. DiFrancesco D, Borer JS. The funny current: cellular basis for the control of heart rate. Drugs 67, Suppl 2: 15-24, 2007.
16. Doesch AO, Ammon K, Konstandin M, Celik S, Kristen A, Frankenstein L, Buss S, Hardt S, Sack FU, Katus HA, Dengler TJ. Heart rate reduction for 12 mo with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation 88: 835-841, 2009.
17. Elbeery JR, Lucke JC, Feneley MP, Maier GW, Owen CH, Lilly RE, Savitt MA, Hickey MS, Gall SA Jr, Davis JW. Mechanical determinants of myocardial oxygen consumption in conscious dogs. Am J Physiol Heart Circ Physiol 269: H609-H620, 1995.
18. Fardoun RZ. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus. Pharmacotherapy 26: 1491-1500, 2006.
19. Gordon SG, Arsenault WG, Longnecker M, Boothe DM, Miller MW, Chalkley J. Pharmacodynamics of carvedilol in conscious, healthy dogs. J Vet Intern Med 20: 297-304, 2006.
20. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153: 1589-1601, 2008.
21. Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol 155: 970-971, 2008.
22. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 29: 2265-2275, 2008.
23. Indolfi C, Guth BD, Miyazaki S, Miura T, Schulz R, Ross J Jr. Heart rate reduction improves myocardial ischemia in swine: role of interventricular blood flow redistribution. Am J Physiol Heart Circ Physiol 261: H910-H917, 1991.
24. Kalaycioglu S, Sinci V, Imren Y, Oz E. Metoprolol prevents ischemiareperfusion injury by reducing lipid peroxidation. Jpn Circ J 63: 718-721, 1999.
25. 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons. Am J Physiol Heart Circ Physiol 286: H1461-H1470, 2004.
26. Korvald C, Elvenes OP, Ytrebo LM, Sorlie DG, Myrmel T. Oxygenwasting effect of inotropy in the "virtual work model". Am J Physiol Heart Circ Physiol 276: H1339-H1345, 1999.
27. Lage-Gallé E, Romero-Rodríguez N, Nevado-Portero J, Guisado-Rasco A, Sobrino-Márquez M, Machuca MG, Fernández-Quero M, Campos-Pareja A, Ballesteros-Pradas S, Martínez-Martínez A. Safety and effectiveness of ivabradine after cardiac transplantation. Transplant Proc 42: 3191-3192, 2010.
28. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol 134: 749-760, 2002.
29. Lucke JC, Elbeery JR, Koutlas TC, Gall SA Jr, D'Amico TA, Maier GW, Rankin JS, Glower DD. Effects of cardiac glycosides on myocardial function and energetics in conscious dogs. Am J Physiol Heart Circ Physiol 267: H2042-H2049, 1994.
30. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 296: H435-H441, 2009.
31. Momose M, Reder S, Raffel DM, Watzlowik P, Wester HJ, Nguyen N, Elsinga PH, Bengel FM, Remien J, Schwaiger M. Evaluation of cardiac beta-adrenoreceptors in the isolated perfused rat heart using (S)-11CCGP12388. J Nucl Med 45: 471-477, 2004.
32. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109: 1674-1679, 2004.
33. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151, 2007.
34. Padua-Filho WC, Brasil DP, Neves HJ, Gomes OM, Bocchi EA. Effects of metoprolol and amiodarone combination on heart rate, myocardial contractility and coronary flow: Study in isolated perfused rat hearts. Exp Clin Cardiol 9: 133-137, 2004.
35. Palatini P. Elevated heart rate: a "new" cardiovascular risk factor? Prog Cardiovasc Dis 52: 1-5, 2009.
36. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP Jr, Barsh GS, Bernstein D, Kobilka BK. Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA 93: 7375-7380, 1996.
37. Sharma V, Dhillon P, Parsons H, Allard MF, McNeill JH. Metoprolol represses PGC1alpha-mediated carnitine palmitoyltransferase-1B expression in the diabetic heart. Eur J Pharmacol 607: 156-166, 2009.
38. Sharma V, Dhillon P, Wambolt R, Parsons H, Brownsey R, Allard MF, McNeill JH. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol 294: H1609-H1620, 2008.
39. Shigetoh Y, Adachi H, Yamagishi S, Enomoto M, Fukami A, Otsuka M, Kumagae S, Furuki K, Nanjo Y, Imaizumi T. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens 22: 151-155, 2009.
40. Skobel E, Dannmann O, Reffelmann T, Böhm V, Weber C, Hanrath P, Uretsky BF, Scharwz ER. Carvedilol protects myocardial cytoskeleton during hypoxia in the rat heart. J Appl Res 5: 378-386, 2005.
41. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129, 2005.
42. Stoll M, Quentin M, Molojavyi A, Thamer V, Decking UK. Spatial heterogeneity of myocardial perfusion predicts local potassium channel expression and action potential duration. Cardiovasc Res 77: 489-496, 2008.
43. Suga H. Minimal oxygen consumption and optimal contractility of the heart: theoretical approach to principle of physiological control of contractility. Bull Math Biol 41: 139-150, 1979.
44. Swoap SJ, Li C, Wess J, Parsons AD, Williams TD, Overton JM. Vagal tone dominates autonomic control of mouse heart rate at thermoneutrality. Am J Physiol Heart Circ Physiol 294: H1581-H1588, 2008.
45. Tardif JC. Heart rate as a treatable cardiovascular risk factor. Br Med Bull 90: 71-84, 2009.
46. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 112: 37-42, 1994.
47. Vaillant F, Timour Q, Descotes J, Manati W, Belhani D, Bui-Xuan B, Tabib A, Bricca G, Chevalier P. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study. J Cardiovasc Pharmacol 52: 548-554, 2008.
48. Vincent G, Khairallah M, Bouchard B, Des Rosiers C. Metabolic phenotyping of the diseased rat heart using 13C-substrates and ex vivo perfusion in the working mode. Mol Cell Biochem 242: 89-99, 2003.
49. Wang P, Zaragoza C, Holman W. Sodium-hydrogen exchange inhibition and beta-blockade additively decrease infarct size. Ann Thorac Surg 83: 1121-1127, 2007.